madman
Super Moderator
“The 2018 AUA guidelines for testosterone therapy that were co-chaired by Dr. John P. Mulhall say that we have an absence or a paucity of data on using testosterone therapy on active surveillance,” says Helen L. Bernie, DO, MPH.
In this video, Helen L. Bernie, DO, MPH, highlights the lack of long-term data on testosterone therapy for men on active surveillance for prostate cancer. Bernie discussed this topic during a panel session at the 2024 American Urological Association Annual Meeting titled, “Controversies in Urology: Testosterone Therapy may be Reasonably Offered to Men on Active Surveillance- Pro/Con.” Bernie is the director of sexual and reproductive medicine at Indiana University and an assistant professor of urology at Indiana University School of Medicine in Indianapolis, Indiana.
Dr. Bernie on testosterone therapy for men on active surveillance
“The 2018 AUA guidelines for testosterone therapy that were co-chaired by Dr. John P. Mulhall say that we have an absence or a paucity of data on using testosterone therapy on active surveillance,” says Helen L. Bernie, DO, MPH.
www.urologytimes.com
In this video, Helen L. Bernie, DO, MPH, highlights the lack of long-term data on testosterone therapy for men on active surveillance for prostate cancer. Bernie discussed this topic during a panel session at the 2024 American Urological Association Annual Meeting titled, “Controversies in Urology: Testosterone Therapy may be Reasonably Offered to Men on Active Surveillance- Pro/Con.” Bernie is the director of sexual and reproductive medicine at Indiana University and an assistant professor of urology at Indiana University School of Medicine in Indianapolis, Indiana.